Latest News for: merkel cell

Edit

Metastatic Merkel Cell Carcinoma Pipeline Insight 2025: Immunotherapies, Targeted Agents, And Novel Biologics Reshape The ...

MENA FN 20 Aug 2025
(MENAFN - GetNews) "Metastatic Merkel Cell Carcinoma Pipeline"The therapeutic pipeline for metastatic Merkel cell carcinoma is advancing rapidly, driven by the urgent need for durable treatments in ... .
Edit

Merkel Cell Carcinoma Market Set for Rapid Growth in the Coming 10 Years Across the ...

Nasdaq Globe Newswire 20 Aug 2025
The market size of Merkel cell carcinoma in the 7MM is expected to increase during the forecast period (2025–2034) due to several factors such as rising global incidence of MCC, rising ...
Edit

Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 14+ Companies and Breakthrough Therapies Shaping the ...

GetNews 15 Aug 2025
Inactive Products Merkel Cell Carcinoma Key Companies Merkel Cell Carcinoma Key Products Merkel Cell Carcinoma- Unmet Needs Merkel Cell Carcinoma- Market Drivers and Barriers Merkel Cell Carcinoma- ...
Edit

Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% Through 2034 ...

GetNews 31 Jul 2025
... Incident Cases, Gender-specific Incident Cases, Stage-specific Incident Cases, Etiology-specific Incident Cases of Merkel Cell Carcinoma, and Total Metastatic Merkel Cell Carcinoma Cases in the 7MM.
Edit

Advanced Merkel Cell Carcinoma Pipeline Outlook Report 2025: Key 20+ Companies and Breakthrough Therapies Shaping ...

GetNews 29 Jul 2025
Inactive Products Advanced Merkel cell carcinoma Key Companies Advanced Merkel cell carcinoma Key Products Advanced Merkel cell carcinoma- Unmet Needs Advanced Merkel cell carcinoma- Market Drivers ...
Edit

Merkel Cell Carcinoma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism ...

MENA FN 28 Jul 2025
(MENAFN - GetNews) "Merkel Cell Carcinoma Clinical Trials"Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte Corporation, Amgen, ... .
Edit

TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma

PR Newswire 24 Jun 2025
... today announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA's lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
Edit

FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma

PR Newswire 09 Jun 2025
... therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S.
  • 1

Article Search

tools
×
×
×
×